Immediate Impact
6 by Nobel laureates 28 from Science/Nature 85 standout
Citing Papers
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
2020 Standout
Challenges and Opportunities in Cancer Drug Resistance
2020 Standout
Works of Todd Covey being referenced
Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile
2017
Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma
2016
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Todd Covey | 542 | 315 | 284 | 658 | 478 | 33 | 1.4k | |
| Jason A. Dubovsky | 686 | 482 | 592 | 564 | 406 | 44 | 1.6k | |
| Günter Brittinger | 655 | 253 | 176 | 548 | 878 | 27 | 1.5k | |
| MF Martelli | 213 | 227 | 397 | 501 | 540 | 29 | 1.2k | |
| Virginia Kelly | 614 | 319 | 442 | 231 | 312 | 34 | 1.2k | |
| DL Longo | 232 | 256 | 232 | 602 | 321 | 31 | 1.2k | |
| David Chiron | 429 | 448 | 207 | 349 | 494 | 50 | 1.2k | |
| Roland Grenningloh | 323 | 401 | 161 | 729 | 270 | 39 | 1.4k | |
| C. R. Barker | 379 | 319 | 142 | 503 | 221 | 39 | 1.1k | |
| Juraj Bodo | 417 | 654 | 247 | 231 | 397 | 47 | 1.3k | |
| M. Wayne Saville | 376 | 216 | 109 | 490 | 593 | 34 | 1.6k |
All Works
Loading papers...